临床试验/NCT05797987

NCT05797987已完成不适用

Negative Estrogen Receptor (ER) Expression Assessed by 18F-fluoroestradiol Positron Emission Tomography/Computed Tomography (18F-FES PET/CT) in the Metastatic Breast Cancer (MBC) With ER-positive Primary Tumor

Fudan University1 个研究点分布在 1 个国家目标入组 52 人开始时间: 2022年12月1日最近更新: 2024年2月26日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方: Fudan University
入组人数: 52
试验地点: 1
主要终点: Progression free survival (PFS)

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

To investigate the treatment pattern and efficacy of patients with positive primary ER lesion but negative ER expression in MBC using a novel convenient way of 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT).

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Retrospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: Female
接受健康志愿者: 否

入选标准

•Patients diagnosed with breast cancer (according to International Classification of Diseases 10th Revision) with confirmed metastasis, regardless of being de novo diagnosed or progressed from a non-metastatic stage.
•MBC patients who underwent 18F-FES PET/CT at the Fudan University Shanghai Cancer Center between 2010 and 2022
•Patients diagnosed with primary ER-positive tumor and who were yet to receive any systemic therapy during the advanced stage

排除标准

•Patients with incomplete medical records and those diagnosed with secondary primary tumors

结局指标

主要结局

Progression free survival (PFS)

时间窗: 6 weeks

次要结局

Adverse events(6 weeks)

研究者

发起方

Fudan University

申办方类型

Other

责任方

Principal Investigator

主要研究者

Biyun Wang, MD

Professor

Fudan University

研究点 (1)

Loading locations...

相似试验

已完成

不适用

Positive ER Expression Assessed by 18F-FES PET/CT in the MBC with ER-negative Primary TumorBreast Cancer

NCT06344767Fudan University19

尚未招募

Unknown

Evaluating utility of Oestrogen and Progesterone Receptor biomarkers for prediction of colorectal Cancer

CTRI/2024/05/068054Datta Meghe Institute of Higher Education & Research (DMIHER)

已完成

2 期

Palbociclib and FES PETBreast Cancer

NCT02806050University Medical Center Groningen30

进行中（未招募）

2 期

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast CancerAdvanced Triple-Negative Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast CarcinomaRecurrent Breast Carcinoma

NCT03941730Mayo Clinic8

招募中

2 期

STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)Metastatic Breast Cancer

NCT05716516Dartmouth-Hitchcock Medical Center36